Overview

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Status:
NOT_YET_RECRUITING

Trial end date:
2029-04-07

Target enrollment:

Participant gender:

Summary

The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Exelixis

Treatments:

cabozantinib
Nivolumab